Although current anticancer immunotherapies using immune checkpoint inhibitors (ICIs)
have been reported with a high clinical success rate, numerous patients still bear …

Skin cancer is a high burden disease with a high impact on global health. Conventional
therapies have several drawbacks; thus, the development of effective therapies is required …

Despite the remarkable progress in immune checkpoint blockade (ICB) therapy for cancer
treatment, low objective response and immune‐related side effects (immune‐related …

With the rapid growth of advanced nanoengineering strategies, there are great implications
for therapeutic immunostimulators formulated in nanomaterials to combat cancer. It is crucial …

Bispecific nanoparticles (NPs) are conjugated with two antibodies that enhance T cell
cytotoxicity by sequentially targeting CD3 and tumor-specific proteins. This interaction …

Standard cancer treatments involve surgery, radiotherapy, chemotherapy, and
immunotherapy. In clinical practice, the respective drugs are applied orally or intravenously …

The body's normal immune response against any invading pathogen that causes infection in
the body results in inflammation. The sudden transformation in inflammation leads to the rise …

Prostate cancer (PCa) responds poorly to routine immunotherapy due to the tumor
immunosuppressive microenvironment. Here, we describe an ultrasound-based drug …

Toll-like receptors (TLRs) are pattern recognition receptors, originally discovered to
stimulate innate immune reactions against microbial infection. TLRs also play essential roles …

Chimeric antigen receptor (CAR) T cell therapy has achieved remarkable clinical success in
the treatment of hematological malignancies. However, producing these bespoke cancer …